Hypothesis

Normal cognitive aging is accompanied by a gain of N6‑methyladenosine (m6A) marks in the 3′UTRs of synaptic transcripts, which enhances their translation via YTHDF1‑dependent mechanisms. This increase acts as a compensatory homeostatic response that sustains synaptic protein synthesis and buffers against age‑related declines in proteostasis. When this m6A‑driven translational boost fails—due to METTL3/METTL14 nuclear loss and cytosolic redistribution observed in Alzheimer’s disease—synaptic protein production collapses, ubiquitin‑mediated proteolysis pathways become hypomethylated and dysregulated, and neurodegeneration ensues. Thus, the age‑associated m6A trajectory reflects a protective adaptive system, not an evolved aging program.

Mechanistic Rationale

1. m6A boosts translation of synaptic proteins – m6A in 3′UTRs recruits YTHDF1, which interacts with eIF3 to promote ribosome loading (1). In aged brains, this mechanism sustains levels of CAMK2, GRIA1, and other plasticity‑related proteins despite declining transcriptional output.
2. Loss of m6A precipitates proteostatic failure – Hypomethylation of ubiquitin‑proteasome genes reduces their m6A‑dependent translation (1), lowering proteasome subunit synthesis and impairing clearance of damaged proteins. Cytosolic METTL3/14 in AD neurons further diminishes nuclear m6A deposition, exacerbating this deficit (2).
3. Adaptive signature – The opposing m6A trajectories in normal aging (gain) versus AD (loss) mirror the distinction between compensatory response and pathological collapse, arguing against a uniform, selected‑for aging program.

Testable Predictions

• Prediction 1: Elevating METTL3 activity specifically in hippocampal neurons of aged (18‑month) mice will increase m6A on synaptic 3′UTRs, raise CAMK2/GRIA1 protein levels, improve LTP and spatial memory, without extending median lifespan.
• Prediction 2: The same METTL3 boost will not restore proteasome activity if ubiquitin‑proteasome transcripts remain hypomethylated, indicating that m6A’s primary role is synaptic translation, not global proteostasis regulation.
• Prediction 3: In METTL3‑overexpressing aged mice, inhibiting YTHDF1 will abolish the cognitive rescue, confirming that the effect depends on m6A‑dependent translation.

Experimental Design

1. Vector – AAV9‑Syn‑METTL3‑WT (or catalytically dead control) injected bilaterally into hippocampus of 18‑month C57BL/6J mice.
2. Readouts (4 weeks post‑injection):
   • MeRIP‑seq for m6A enrichment on synaptic 3′UTRs.
   • Western blot / quantitative proteomics for CAMK2, GRIA1, proteasome subunits.
   • Electrophysiology (LTP) and behavioral assays (Morris water maze, novel object recognition).
   • Survival monitoring to assess lifespan impact.
3. Intervention arms:
   • METTL3‑WT vs. METTL3‑dead.
   • METTL3‑WT + YTHDF1 shRNA (to test dependence).
   • METTL3‑WT + proteasome activator (to test additive effects).

Falsifiability

If METTL3 overexpression fails to increase synaptic m6A or protein levels, or if it does improve cognition and significantly prolongs lifespan, the hypothesis that m6A acts as a non‑programmed adaptive buffer would be weakened. Conversely, a rescue of cognition without lifespan extension would support the view that aging’s molecular changes are largely compensatory, and that therapeutic strategies should aim to bolster these responses rather than counteract a presumed aging program.